title: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
abstract: A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome. Here we analyze treatment outcome of an enlarged series of patients who have been followed up for a median of 65 months. From November 1999 through July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin. Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy. The 5-year cumulative incidence of relapse and disease-free survival were 11% and 84%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P = .019 and P = .04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy.
authors.affiliation: Hospital Universitario La Fe, Valencia, Spain. msanz@uv.es
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Sanz
authors.forename: Pau
authors.initials: P
authors.lastname: Montesinos
authors.forename: Edo
authors.initials: E
authors.lastname: Vellenga
authors.forename: Consuelo
authors.initials: C
authors.lastname: Rayón
authors.forename: Javier
authors.initials: J
authors.lastname: de la Serna
authors.forename: Ricardo
authors.initials: R
authors.lastname: Parody
authors.forename: Juan M
authors.initials: JM
authors.lastname: Bergua
authors.forename: Angel
authors.initials: A
authors.lastname: León
authors.forename: Silvia
authors.initials: S
authors.lastname: Negri
authors.forename: Marcos
authors.initials: M
authors.lastname: González
authors.forename: Concha
authors.initials: C
authors.lastname: Rivas
authors.forename: Jordi
authors.initials: J
authors.lastname: Esteve
authors.forename: Gustavo
authors.initials: G
authors.lastname: Milone
authors.forename: José D
authors.initials: JD
authors.lastname: González
authors.forename: Elena
authors.initials: E
authors.lastname: Amutio
authors.forename: Salut
authors.initials: S
authors.lastname: Brunet
authors.forename: J
authors.initials: J
authors.lastname: García-Laraña
authors.forename: Dolors
authors.initials: D
authors.lastname: Colomer
authors.forename: María J
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: Carmen
authors.initials: C
authors.lastname: Chillón
authors.forename: Eva
authors.initials: E
authors.lastname: Barragán
authors.forename: Pascual
authors.initials: P
authors.lastname: Bolufer
authors.forename: Bob
authors.initials: B
authors.lastname: Lowenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D014212:Tretinoin